Ariana Pelosci

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.

The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.

Under a new FDA initiative, the agency recently updated a decades’ old approval of the chemotherapy capecitabine. This move, according to an expert, will springboard further change in the treatment of cancer.

The findings, according to a group of researchers, warrant the development of treatments that attack HER2-low advanced gastric cancer.

The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.

Experts present patient cases of those with transplant-eligible or ineligible multiple myeloma and discuss the current standard of care treatment, and how to apply it to their patients.

The FDA’s decision to approve mosunetuzumab marks the first bispecific antibody approved to treat follicular lymphoma.

Results from the phase 2 ARC-7 trial found that zimberelimab, etrumadenant, and domvanalimab enhanced efficacy outcomes in patients with advanced non–small cell lung cancer.

During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways.

Patients with KRAS G12C–mutated non–small cell lung cancer can now receive adagrasib therapy following the treatment’s recent accelerated approval by the FDA.

The phase 2 ELARA trial indicated continued durable responses when patients with relapsed/refractory follicular lymphoma were treated with tisagenlecleucel.

The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Results from a phase 2 trial indicated that subgroups of patients with advanced or metastatic sarcoma may benefit from durvalumab plus tremelimumab, with data encouraging further evaluation in the population.

Results from the ongoing phase 2 IMMUNOCERV trial showed that treatment with the investigational drug PDS0101 — a vaccine — combined with chemotherapy and radiation induced a 100% clinical response in a small group of patients with stage IB3 to IVA cervical cancer.

The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.

Data from a study indicated that durable minimal residual disease negativity was associated with stool butyrate production in patients with multiple myeloma who had plant-based diets undergoing treatment with lenalidomide maintenance.

The FDA has approved tremelimumab plus durvalumab for patients with metastatic non–small cell lung cancer based on findings from arms 1 and 3 of the phase 3 POSEIDON trial.

Findings from a phase 3 trial assessing nomacopan in patients with hematopoietic stem cell transplant–related thrombotic microangiopathy helped to support a rare pediatric designation from the FDA for the agent.

Based on results of the phase 3 EMPOWER-Lung3 trial, frontline use of cemiplimab plus chemotherapy has been approved by the FDA for patients with advanced non–small cell lung cancer.

The primary end point of progression-free survival was not met in the phase 3 DREAMM-3 trial which investigated belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Patients with advanced solid tumors treated with milademetan experienced promising anti-tumor activity at the interim analysis for the phase 2 MANTRA-2 basket trial.

Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.

Results from the phase 1 ARROS-1 trial showed NVL-520 may stop tumor growth and yielded response in brain metastases in patients with ROS1-positive non–small cell lung cancer and other solid tumors.

An abbreviated new drug application was granted approval by the FDA for leuprolide acetate injection for patients with advanced prostate cancer.

A recent study found that giving sinoatrial node radiation therapy during chemoradiotherapy may increase the likelihood of atrial fibrillation in patients with small cell lung cancer and non–small cell lung cancer.

At ASTRO 2022, Phuoc Tho Tran, MD, spoke about the potential benefit of combining salvage radiation therapy and enzalutamide vs placebo in patients with high-risk prostate-specific antigen–recurrent prostate cancer after radical prostatectomy.

Based on results from the phase 1/2 MajesTec-1 trial, the FDA has granted accelerated approval to teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.

Results from the phase 2 NRG-HN004 trial found durvalumab plus radiotherapy did not show improved progression-free survival vs cetuximab in patients with locoregionally advanced head and neck cancer who had a contraindication to cisplatin.

Based on results from the phase 3 HIMALAYA trial, the FDA has approved tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma.